Edition:
United States

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Global Select Market

2.30USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$2.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,239
52-wk High
$4.79
52-wk Low
$2.27

VICL.OQ

Chart for VICL.OQ

About

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including... (more)

Overall

Beta: 2.00
Market Cap(Mil.): $30.28
Shares Outstanding(Mil.): 11.05
Dividend: --
Yield (%): --

Financials

  VICL.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.90 -- --
ROI: -17.86 -1.09 14.95
ROE: -17.95 -2.39 16.29

BRIEF-Vical reports Q3 loss per share $0.24

* Vical Inc says projecting net cash burn for 2016 between $8 million and $11 million

Nov 03 2016

BRIEF-Vical initiates phase 2 trial of HSV-2 therapeutic DNA vaccine

* Vical announces initiation of a phase 2 trial of its HSV 2 therapeutic DNA vaccine for genital herpes

Sep 26 2016

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

Sep 19 2016

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

Sep 19 2016

BRIEF-Anges MG to work together with Vical Incorporated on DNA vaccine business

* Says the company and Vical Incorporated has agreed to work together on DNA vaccine business, which includes research, development and manufacturing

Aug 12 2016

BRIEF-Vical Q2 loss per share $0.14

* Projecting net cash burn for 2016 between $8 million and $11 million Source text for Eikon: Further company coverage:

Aug 09 2016

BRIEF-Vical announces $7.8 mln equity investment by partner Anges MG

* Vical announces $7.8 million equity investment by partner, Anges MG

Aug 01 2016

BRIEF-AnGes MG to invest Vical and to hold 18.6 pct stake in it

* Says it to buy 1,841,420 shares of Vical Inc for $4.2448 per share on Aug. 3

Aug 01 2016

BRIEF-Vical's phase 1/2 trial data shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months

* Initial top line 3-month data announced in june 2015 showed neither monovalent nor bivalent vaccine met primary endpoint of viral shedding rate reduction from baseline

Jun 20 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €74.58 -1.48
Novartis AG (NOVN.S) CHF69.30 -0.20
GlaxoSmithKline plc (GSK.L) 1,452.00p -7.00
AstraZeneca plc (AZN.L) 4,007.30p -26.00
Merck & Co., Inc. (MRK.N) $60.25 -0.88
Pfizer Inc. (PFE.N) $31.59 -0.04
Roche Holding Ltd. (ROG.S) CHF223.30 +1.20
Roche Holding Ltd. (RO.S) CHF226.20 +0.20
Genocea Biosciences Inc (GNCA.OQ) $3.89 --
Agenus Inc (AGEN.OQ) $4.31 +0.21

Earnings vs. Estimates